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Three patients with Budd-Chiari syndrome (BCS) and fresh inferior vena cava (IVC) thrombosis were treated by
agitation thrombolysis as a mechanical thrombectomy procedure and followed up by duplex ultrasonography.
Agitation thrombolysis was technically and clinically successful in all patients. Inferior vena cavagrams after the
procedure showed complete resolution of the iatrogenic, fresh IVC thrombi without occurrence of pulmonary
embolism. Duplex ultrasonography follow-ups after 12, 24, and 28 months, respectively, confirmed complete
patency of the IVC without rethrombosis and reobstruction. The results indicate that agitation thrombolysis may be
a safe and feasible approach for BCS patients with iatrogenic, fresh IVC thrombosis. ( J Vasc Surg 2010;52:782-4.)Primary Budd-Chiari syndrome (BCS) is a rare form of
hepatic venous outflow obstruction at the suprahepatic infe-
rior vena cava (IVC), thehepatic veins, or both.BCSwith IVC
thrombosis, particularly with acute, fresh thrombosis, is the
rarest form. A number of thrombolytic agents, such as the
acylated streptokinase-plasminogen complex, urokinase,
streptokinase (all three of which are no longer available in the
United States), and tissue plasminogen activator have been
administered either through a peripheral intravenous route or
catheter-mediated through a catheter into the inferior vena
cava or hepatic vein, successfully dissolving the fresh clots.1-4
These procedures, however, are slow, time-consuming, and
cannot ensure complete resolution of the fresh clots. To
overcome the unmet clinical need,we devised a quick and easy
thrombolytic approach; that is, agitation thrombolysis for the
treatment of BCS patients with iatrogenic, fresh thrombosis.
The purpose of our study was to report our preliminary
technical and clinical experience with this approach in the
treatment of three BCS patients with iatrogenic, fresh throm-
bosis.
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782MATERIALS AND METHODS
Patients. Between August 2004 and March 2009, 298
patients with BCS were treated with balloon dilation to re-
establish patency and were subsequently followed up by du-
plex ultrasonography (GE Vivid 7 Pro; GE, Calif) at our
hospital. Three of the BCS patients (two men, one woman;
mean age 41.67 5.51 years [range, 36-47 years]; see Table)
with iatrogenic, fresh IVC thrombosis after failure of rupture
of the occluded IVC were treated by agitation thrombolysis
prior to balloon dilation. Before treatment start, informed
consent had been obtained from each patient, and the study
was approved by our local ethics committee.
Agitation thrombolysis procedure. Prior to the pro-
cedure, during which the patients were monitored continu-
ously for vital signs and bleeding complications, inferior vena
cavagraphy of the right groin revealed the location and size of
the thrombus and the occluded section of the IVC (Fig 1a, b).
Patients received a bolus of 5000 IUheparin at the start of the
procedure, followed by a continuous infusion of 1000 IU/
hour to keep the activated clotting time above 300 seconds.
Then a J-type Brockenbrough needle (Cook, Inc, Blooming-
ton, Ind) was transfemorally introduced into the distal part of
the obstruction, followedby a 5Fr Pigtail catheter (Cook, Inc)
inserted into the proximal area of the obstruction by using the
right jugular vein as the marker for the needle. Under multi-
angled fluoroscopy guidance, the angle of the needle was
adjusted to ensure that the needle was directed at the catheter
at the proximal part of the obstruction. At this point, the
obstruction was penetrated slowly.5
After rupture of the IVCmembranes, a 5F pigtail catheter
was inserted into the IVCwith its tip positioned at the level of
the fresh IVC thrombosis. A Nipan guide wire (Radifocus;
Terumo,Tokyo, Japan)with a helical tip configuration,which
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through the catheter until its tip configured into a helical
configuration in the targeted IVC (Fig 1c). The catheter and
the guide wire were alternatively rotated clockwise and anti-
clockwise or pushed and drawn up and down to agitate and
break the thrombosis, while a bolus of 10 to 20 mL mixed
urokinase (1-2  104 U) was injected intermittently to dis-
solve the fresh thrombus. To visualize the status of the IVC
thrombus during the procedure, 10 to 20 mL iopromide
contrast medium (Ultravist, Berlex Laboratories, Montville,
NJ) was injected manually through the catheter.
After completion resolution of the fresh thrombus, a
30-mm balloon catheter (Cook, Inc) was inserted and
positioned at the obstructive IVC. Then, the balloon was
dilated with the contrast medium to get a full expansion
of the IVC. Immediately after the procedure, an inferior
vena cavagraphy was performed to confirm complete
resolution of the fresh IVC thrombus as well as a satis-
factory IVC blood flow (Fig 1d).
To prevent rethrombosis, heparin was given for 48
hours after the procedure, and warfarin (5 mg/day) was
administered orally from the beginning of the second day
until 3 to 6months after the procedure. The IVC follow-up
protocols were performed at 1 week and 1, 3, 6, and 12
months after the procedure and then annually by duplex
ultrasonography (Fig 1e).
RESULTS
Agitation thrombolysis in the IVC was clinically suc-
cessful and well tolerated without any complications in all
three patients. The inferior vena cavagrams performed im-
mediately after the procedure, demonstrated complete res-
olution of the thrombi and full IVC patency. Duplex ultra-
sonography follow-ups after 12, 24, and 28 months
posttreatment showed full IVC patency, without rethrom-
bosis, restenosis, or reobstruction of the treated IVC. The
clinical follow-ups after 16, 30, and 30 months showed full
recovery of all patients, without relapse of the clinical
symptoms at time of treatment start.
DISCUSSION
We presented agitation thrombolysis as an easy and fast
procedure to quickly dissolve iatrogenic, fresh IVC thrombi in
three patients with BCS. Agitation thrombolysis was clinically
and technically successful in all patients. Inferior vena cava-
Table. Demographic and clinical presentation of three BC
Pa./age/
gender
Dur.
(m) Symptoms
Thrombosis (mm)
Location Length Diam
1/M/47 120 AP, H, S, VT, LE, P IVC 20 22
2/F/36 24 VT, AP, H, S, LE, P IVC 45 26
3/M/42 60 VT, AP, H, S, GB, P IVC 40 28
AP, Abdominal pain and distention; Dur, duration of the symptoms; GB
membranous obstruction; P, pigmentation; Pa, patient; S, splenomegaly; Vgrams and color Doppler ultrasound results up to 12, 24, or28 months after the procedure demonstrated complete reso-
lution of the iatrogenic, fresh IVC thrombi. Furthermore, to
date, our patients have not experienced any recurrence of
clinical symptoms, such as pulmonary embolization.
Fresh clinical thrombosis can occur naturally or iatro-
genically. In Asia, membranous obstruction of the IVC or
the hepatic vein or both is the most common cause of BCS
and accounts for up to 60% to 70% of the total patient
number.5-8 In these BCS patients, thrombi are easily
formed due to obstruction at the suprahepatic IVC, the
slow, turbulent or reverse blood flow in the IVC, and the
hypercoagulable blood state. Mostly, IVC thrombosis in
the BCS patients presenting in our hospital is already
chronic, since onset of the disease is often nonsymptomatic,
and the onset time is therefore often difficult to track down.
Therefore, we only rarely see BCS patients presenting with
natural, fresh IVC thrombosis, whereas cases of iatrogenic,
fresh thrombosis are more common.
The causes of iatrogenic thrombosis may be as fol-
lows: inferior vena cavagraphy or failure of rupture of
occluded IVC; IVC endothelial cell damage by high
concentration of contrast medium or manipulation of
the catheter, guide wire, or other instruments during the
procedure; missed or underdosed anticoagulation ther-
apy after the procedure; or application of antihemor-
rhagic therapy in BCS patients with hemorrhage.
The reasons of iatrogenic IVC thrombosis in our pa-
tients were previous failure of rupture of occluded IVC,
lack of anticoagulation therapy, and application of antihem-
orrhagic therapy, respectively. Thus, we usually perform
diagnostic inferior vena cavagraphy as a potential cause of
iatrogenic thrombosis in our BCS patients only if deemed
necessary, and we routinely administer standard anticoag-
ulation therapy after thrombus resolution to prevent sec-
ondary thrombosis.
Currentmedication or procedures to treat IVC thrombo-
sis include thrombolytic agents,1 transjugular intrahepatic
portosystemic shunts,9 surgical shunts,10 balloon angioplasty,
metallic stents,2,3 and retrieval stent filters.4 However, these
methods are normally used for only chronic (rather than fresh)
thrombosis, and they are complicated to use, expensive, and at
high risk of causing bleeding. Continuous injection of throm-
bolytic agents may be useful;1-4 however, the injection dura-
tion is long, and complete resolution of the fresh IVC clots
cannot be guaranteed. Our agitating thrombolysis procedure
tients with fresh IVC thrombosis
Thrombolysis
time (min)
Dosage of
urokinase
Duplex
ultrasonography
follow-up (m)
Follow-
up (m) Outcome
20 20  104 U 12 30 Alive
20 30  104 U 28 30 Alive
20 25  104 U 24 16 Alive
rointestinal bleeding; H, hepatomegaly; LE, lower extremity edema; MB,
ices in thoracico-abdominal and legs.S pa
eterhas the following advantages: 1) easy and fast to apply; 2) use
rethrombosis at 1-year postprocedure.
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embolization due to attaining complete thrombus resolu-
tion; and 4) additional treatment procedures such as bal-
loon dilation or stent placement can be performed imme-
diately after the procedure, thus avoiding reintervention.
Study limitations. Our study is a single-center, short-
term case study including only three patients. The long-term
efficacy of our agitation thrombolysis procedure for treating
fresh IVC thrombosis in BCS patients warrants further inves-
tigation in larger, controlled studies.
In summary, our preliminary results indicate that agi-
tation thrombolysis by using a guide wire and a catheter
may be a safe and feasible approach in BCS patients with
iatrogenic, fresh IVC thrombosis.
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Submitted Dec 5, 2009; accepted Feb 6, 2010.Fig 1. Visualization of the inferior vena cava (IVC) of a 47-
year-old man with a 10-year history of Budd-Chiari syndrome
(BCS). (a) Baseline IV cavagram reveals membranous obstruc-
tion with no thrombus. (b) IV cavagram exhibits a triangle fresh
thrombosis at the top of the obstructed IVC (arrowhead). (c)
Anteroposterior fluoroscopy image shows the helical configura-
tion of the guide wire in the IVC (arrowhead) after rupture of
the membranous obstruction during the procedure. (d) IV
cavagram performed immediately after agitation thrombolysis
and balloon dilation demonstrates complete dissolution of the
thrombus with full IVC patency. (e) Two-dimensional, longi-
tudinal color Doppler sonogram confirms IVC patency without
